Karyopharm Therapeutics (KPTI) Received $19.0000 Target From Wedbush; Shorts at Ballard Power Systems Inchares (BLDP) Raised By 3.01%

May 24, 2018 - By Winifred Garcia

Ballard Power Systems Inc. (NASDAQ:BLDP) Logo

Karyopharm Therapeutics (NASDAQ:KPTI)‘s rating was downgraded by investment analysts at Wedbush to a Hold rating in a analysts report revealed to investors and clients on Thursday, 24 May. The firm currently has a $19.0000 target price on the stock. Wedbush’s target price gives a potential downside of -0.31%.

Ballard Power Systems Inchares (NASDAQ:BLDP) had an increase of 3.01% in short interest. BLDP’s SI was 8.12 million shares in May as released by FINRA. Its up 3.01% from 7.89 million shares previously. With 1.17 million avg volume, 7 days are for Ballard Power Systems Inchares (NASDAQ:BLDP)’s short sellers to cover BLDP’s short positions. The SI to Ballard Power Systems Inchares’s float is 5.08%. The stock increased 0.98% or $0.03 during the last trading session, reaching $3.08. About 539,796 shares traded. Ballard Power Systems Inc. (NASDAQ:BLDP) has risen 59.46% since May 24, 2017 and is uptrending. It has outperformed by 47.91% the S&P500.

More recent Ballard Power Systems Inc. (NASDAQ:BLDP) news were published by: Fool.com which released: “Better Fuel Cell Stock: Plug Power (PLUG) vs. Ballard Power Systems (BLDP)” on May 20, 2018. Also Seekingalpha.com published the news titled: “Ballard Power Systems’ (BLDP) CEO Randall MacEwen on Q1 2018 Results – Earnings Call Transcript” on May 02, 2018. Fool.com‘s news article titled: “Is Ballard Power Systems (BLDP) a Buy?” with publication date: May 12, 2018 was also an interesting one.

Among 4 analysts covering Ballard Power Systems (NASDAQ:BLDP), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Ballard Power Systems had 16 analyst reports since August 20, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Monday, July 31 by Roth Capital. On Friday, August 4 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright reinitiated it with “Buy” rating and $2.50 target in Thursday, August 20 report. The stock of Ballard Power Systems Inc. (NASDAQ:BLDP) has “Hold” rating given on Thursday, July 13 by Cowen & Co. The stock of Ballard Power Systems Inc. (NASDAQ:BLDP) earned “Hold” rating by Cowen & Co on Friday, September 15. The stock has “Buy” rating by Rodman & Renshaw on Thursday, August 20. On Thursday, January 4 the stock rating was maintained by Roth Capital with “Hold”. The stock of Ballard Power Systems Inc. (NASDAQ:BLDP) earned “Buy” rating by H.C. Wainwright on Friday, March 2. On Thursday, June 22 the stock rating was maintained by FBR Capital with “Buy”. Cowen & Co maintained the shares of BLDP in report on Monday, October 16 with “Hold” rating.

Ballard Power Systems Inc. engages in the design, development, manufacture, sale, and service of proton exchange membrane fuel cells worldwide. The company has market cap of $548.77 million. The Company’s power products include stationary systems, such as FCgen-H2PM, a hydrogen-fueled power system for telecommunications network, secure communications, and critical data communications, as well as hub, transmission, or repeater sites applications; and motive modules, including FCveloCity, a PEM fuel cell stack, which provides solutions for forklifts, buses, and light rails. It currently has negative earnings. The companyÂ’s power products also comprise FCgen air-cooled and FCvelocity liquid-cooled fuel cell stacks to power fuel cell systems for a range of applications, as well as portable power products comprising fuel cell power solutions for portable, remote, and mobile applications.

The stock increased 1.28% or $0.24 during the last trading session, reaching $19.06. About 366,001 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since May 24, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Streetinsider.com which released: “Karyopharm Therapeutics (KPTI), Antengene Sign Pact to Develop and Commercialize Selinexor, Eltanexor …” on May 24, 2018, also Seekingalpha.com with their article: “Karyopharm Impresses In Refractory Multiple Myeloma Trial” published on May 01, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on May 24, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay” published on May 02, 2018 as well as Globenewswire.com‘s news article titled: “Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock” with publication date: May 03, 2018.

Investors sentiment decreased to 1.56 in Q4 2017. Its down 0.94, from 2.5 in 2017Q3. It fall, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported. Swiss National Bank & Trust owns 56,850 shares. Baker Bros L P reported 0.02% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Deutsche Natl Bank Ag holds 0% or 188,373 shares. Manufacturers Life Ins Co The reported 26,729 shares or 0% of all its holdings. Services Automobile Association holds 0% or 81,670 shares. Citadel Advisors Ltd Liability Corporation has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Geode Management Ltd Liability Corporation invested in 0% or 280,610 shares. Tudor Invest Et Al, Connecticut-based fund reported 22,836 shares. State Board Of Administration Of Florida Retirement System owns 14,761 shares. C Gru Holdings A S owns 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 16,048 shares. D E Shaw & Company holds 0% or 72,771 shares. Proshare Limited Co holds 0% or 30,437 shares in its portfolio. Franklin Res reported 3.34 million shares. First Personal Fincl holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 1,187 shares. California State Teachers Retirement Systems accumulated 53,278 shares.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $24.50’s average target is 28.54% above currents $19.06 stock price. Karyopharm Therapeutics Inc. had 38 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, April 30 by Cantor Fitzgerald. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Thursday, November 2 by RBC Capital Markets. The firm has “Buy” rating by Jefferies given on Tuesday, August 30. The company was downgraded on Tuesday, March 15 by Bank of America. The stock has “Buy” rating by Jefferies on Wednesday, April 25. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by Jefferies on Thursday, October 12. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Tuesday, May 15 by Canaccord Genuity. The firm has “Buy” rating given on Thursday, January 11 by H.C. Wainwright. The firm earned “Buy” rating on Friday, March 2 by RBC Capital Markets. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by Cantor Fitzgerald on Friday, June 23.

Since December 11, 2017, it had 0 insider purchases, and 31 insider sales for $3.58 million activity. Shares for $100,882 were sold by Kauffman Michael on Thursday, January 18. Shacham Sharon had sold 10,000 shares worth $125,048. The insider Primiano Christopher Brett sold $40,076. Another trade for 2,500 shares valued at $42,525 was made by Mirza Mansoor Raza on Monday, March 12.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.15 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin??s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>